250 related articles for article (PubMed ID: 34893606)
1. KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma.
D'Oto A; Fang J; Jin H; Xu B; Singh S; Mullasseril A; Jones V; Abu-Zaid A; von Buttlar X; Cooke B; Hu D; Shohet J; Murphy AJ; Davidoff AM; Yang J
Nat Commun; 2021 Dec; 12(1):7204. PubMed ID: 34893606
[TBL] [Abstract][Full Text] [Related]
2.
De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
[TBL] [Abstract][Full Text] [Related]
3. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
5. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
[TBL] [Abstract][Full Text] [Related]
6. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
7. KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer.
Cao Z; Shi X; Tian F; Fang Y; Wu JB; Mrdenovic S; Nian X; Ji J; Xu H; Kong C; Xu Y; Chen X; Huang Y; Wei X; Yu Y; Yang B; Chung LWK; Wang F
Cell Death Dis; 2021 Jan; 12(1):2. PubMed ID: 33414463
[TBL] [Abstract][Full Text] [Related]
8. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
[TBL] [Abstract][Full Text] [Related]
9. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.
Abu-Zaid A; Fang J; Jin H; Singh S; Pichavaram P; Wu Q; Tillman H; Janke L; Rosikiewicz W; Xu B; Van De Velde LA; Guo Y; Li Y; Shendy NAM; Delahunty IM; Rankovic Z; Chen T; Chen X; Freeman KW; Hatley ME; Durbin AD; Murray PJ; Murphy AJ; Thomas PG; Davidoff AM; Yang J
Cell Rep Med; 2024 Mar; 5(3):101468. PubMed ID: 38508144
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer.
Zhang J; Ying Y; Li M; Wang M; Huang X; Jia M; Zeng J; Ma C; Zhang Y; Li C; Wang X; Shu XS
Theranostics; 2020; 10(22):10016-10030. PubMed ID: 32929331
[TBL] [Abstract][Full Text] [Related]
11. KDM6B promotes ESCC cell proliferation and metastasis by facilitating C/EBPβ transcription.
Qin M; Han F; Wu J; Gao FX; Li Y; Yan DX; He XM; Long Y; Tang XP; Ren DL; Gao Y; Dai TY
BMC Cancer; 2021 May; 21(1):559. PubMed ID: 34001062
[TBL] [Abstract][Full Text] [Related]
12. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
13. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
Liu Y; Liu D; Wan W
Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
[TBL] [Abstract][Full Text] [Related]
14. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
[TBL] [Abstract][Full Text] [Related]
15. Epigenomic profiling of neuroblastoma cell lines.
Upton K; Modi A; Patel K; Kendsersky NM; Conkrite KL; Sussman RT; Way GP; Adams RN; Sacks GI; Fortina P; Diskin SJ; Maris JM; Rokita JL
Sci Data; 2020 Apr; 7(1):116. PubMed ID: 32286315
[TBL] [Abstract][Full Text] [Related]
16. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
17. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
Yang J; AlTahan AM; Hu D; Wang Y; Cheng PH; Morton CL; Qu C; Nathwani AC; Shohet JM; Fotsis T; Koster J; Versteeg R; Okada H; Harris AL; Davidoff AM
J Natl Cancer Inst; 2015 Jun; 107(6):djv080. PubMed ID: 25925418
[TBL] [Abstract][Full Text] [Related]
18. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
19. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
20. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]